Cormedix Rg

CorMedix Inc. develops DefenCath, an antimicrobial catheter lock solution reducing bloodstream infections in adult dialysis patients, poised to capture a high‑growth critical‑care niche.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 64
HQ: Berkeley Heights

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CRMD	Cormedix Rg Cap: 0.6B \| P/E: 3.5	EQUITY	NMS	USD	US21900C3088	Active	📈